CMC & ManufacturingLast reviewed April 2026

EU GMP Annex 1(Annex 1)

The EU GMP annex establishing requirements for the manufacture of sterile medicinal products.

Usage Examples

The Contamination Control Strategy per Annex 1 documented the holistic approach to preventing sterility failures.
Grade A air classification was maintained throughout the filling zone with continuous viable and non-viable monitoring.

What is Annex 1?

EU GMP Annex 1 is the European Medicines Agency's regulatory framework for sterile product manufacturing. The 2022 revision (effective 25 August 2023, lyophilization provisions effective 25 August 2024) represented the most significant update in decades, introducing explicit Contamination Control Strategy (CCS) requirements, quality risk management integration, and modernized cleanroom classification expectations.

Annex 1 covers cleanroom classification (Grade A, B, C, D), personnel gowning and qualification, environmental monitoring, equipment and facility design, aseptic process validation (media fills), sterilization processes, and contamination control across the full manufacturing lifecycle. It applies to sterile drug products (injectables, ophthalmics, topical sterile products) and certain sterile medical devices. FDA's aseptic processing guidance (2004, revision pending) aligns broadly but not identically; global sterile manufacturers typically meet both.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside EUDRALEX VOLUME 4 ANNEX 1, EU GMP, FDA ASEPTIC GUIDANCE.

FDAICHHealth Canada

When This Matters

The Contamination Control Strategy per Annex 1 documented the holistic approach to preventing sterility failures.
Grade A air classification was maintained throughout the filling zone with continuous viable and non-viable monitoring.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

EUDRALEX VOLUME 4 ANNEX 1EU GMPFDA ASEPTIC GUIDANCE

Frequently Asked Questions

Directly only to EU-destined sterile products. However, most global manufacturers meet Annex 1 expectations because (a) EU market access requires it, (b) international harmonization is increasing, and (c) Annex 1 represents current state of the art that FDA often cites during inspections.

Explicit Contamination Control Strategy (CCS) requirement, quality risk management integration throughout, updated cleanroom classification, enhanced requirements for single-use systems, and strengthened environmental monitoring expectations. The revision modernizes a document largely unchanged since 2008.

Terminal sterilization is preferred whenever the product can tolerate it — it provides higher sterility assurance. Aseptic processing is used for heat-sensitive products that cannot withstand terminal sterilization. Annex 1 requires justification when aseptic processing is chosen over terminal sterilization.